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1. Introduction  
Colorectal cancer (CRC) is the third most frequent cancer type and the second leading cause 
of cancer-related deaths worldwide (Cunningham et al., 2010; Jemal et al., 2010). This is 
despite the recent trend of stabilizing or declining rates for CRC incidence and mortality in 
economically developed countries (Center et al., 2009; Edwards et al., 2010; Umar & 
Greenwald, 2009). Surgical intervention is the initial treatment for most CRC patients. 
Continuous efforts to optimize surgery for patients with localized CRC has resulted in 
markedly improved 5-year and 10-year survival rates (Cunningham et al., 2010; Wu & Fazio, 
2000). Given the large number of CRC patients who undergo curative surgery, there is now 
a substantial number who are susceptible to recurrent or metastatic tumors and could 
therefore benefit from additional systemic therapies. An increasing array of options and 
protocols for chemotherapies and biologically targeted therapies is now available for use in 
the adjuvant setting and for the treatment of recurrent and metastatic CRC. 
Based on a more detailed knowledge of the molecular characteristics of CRC (Markowitz et 
al., 2009; Walther et al., 2009), biologically-based therapeutics have been developed for the 
treatment of advanced stage CRC patients. Currently approved agents for the treatment of 
advanced and metastatic CRC include therapeutic monoclonal antibodies that target 
vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR). 
Despite a substantial biological rationale for the use of these new classes of therapeutic 
agents, large-scale clinical trials have observed only incremental clinical benefits for overall 
patient populations. Clearly, not all patients with recurrent and metastatic CRC benefit from 
these therapies. This is due to inherent and acquired resistance of tumors to the 
chemotherapeutic and biologically-based agents. Moreover, there are few reliable markers 
for predicting the therapeutic and adverse effects of these agents and that would allow 
patients who benefit from these systemic treatments to be identified. Therefore, new 
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therapeutic targets are urgently required to further improve the survival of patients with 
recurrent and metastatic CRC. One such target may be glycogen synthase kinase 3ǃ 
(GSK3ǃ), a serine/threonine protein kinase that has recently been implicated in various 
human cancers.  
In this Chapter, we briefly summarize the scientific basis and current status of systemic 
treatments for CRC, including combinations of surgery, chemotherapy and molecular 
target-directed therapy. Based on our published and ongoing studies, we then focus on 
GSK3ǃ as an emerging therapeutic target in CRC and other cancer types. We describe the 
underlying biological mechanism that allows exploration of a novel therapeutic strategy for 
CRC involving the targeting of aberrant GSK3ǃ. 
2. Molecular basis of colorectal cancer 
2.1 Multistep and multiple molecular alterations 
Colorectal carcinogenesis displays all the major biological hallmarks of cancer (Hanahan & 
Weinberg, 2011). CRC evolves and develops through orchestrated, multistep genetic and 
epigenetic alterations in oncogenes, tumor suppressor genes and DNA mismatch repair 
genes. These include frequent aberrations in certain chromosomes, such as allelic imbalance 
at several chromosomal loci (e.g., chromosome 5q, 8p, 17p, 18q) and chromosome 
amplification and translocation. Various combinations of somatic and germ-line alterations 
in these genes and chromosomes characterize the different genotypes and phenotypes of 
sporadic and hereditary forms of CRC (Cunningham et al., 2010; Markowitz & Bertagnolli, 
2009; Walther et al., 2009). Among the genes involved in the molecular process of CRC 
development, several genetic markers have been reported to harbor diagnostic and 
prognostic information and to predict the benefit from or resistance to systemic therapy 
(Ellis & Hicklin, 2009; Markowitz & Bertagnolli, 2009; Walther et al., 2009). 
Recent advances in DNA sequencing technology have allowed sequencing of the entire 
coding genome of human cancer to become a reality. The high throughput, next-generation 
sequencing of 18,000 genes in the Reference Sequence data-base of the National Center for 
Biotechnology Information in the USA has identified cancer-associated somatic mutations in 
848 genes. Amongst these, 140 are considered as candidate genes responsible for the 
development and phenotype of CRC (Sjőblom et al., 2006; Wood et al., 2007). 
2.2 Oncogene addiction 
The unrestrained survival and proliferation of cancer cells relies on distinct oncogenic 
signalling pathways in which various oncoproteins, growth factor receptors and their 
ligands are aberrantly activated, leading to the concept of “oncogene addiction” (Sharma & 
Settleman, 2007; Weinstein, 2002; Weinstein & Joe, 2006). In theory, acute ablation of 
oncogene function should lead to the rapid dissipation of its pro-survival signal in cancer 
cells, thus resulting in apoptotic cell death. This “oncogenic shock” concept underlies the 
strategy of molecular targeting in cancer therapy (Sharma et al., 2006). The scientific 
rationale behind the development and application of therapeutic monoclonal antibodies 
targeting VEGF and EGFR for the treatment of CRC is based on these concepts. Intriguingly, 
however, the EGFR expression level in primary CRC determined by immunohistochemistry 
was not observed to correlate with the efficacy of therapeutic anti-EGFR antibodies in 
clinical trials of metastatic CRC (Hecht et al., 2010; commented by Grothey, 2010). 
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3. Systemic treatment: An overview 
Surgery remains the cornerstone for the cure of localized CRC (Cunningham et al., 2010; Wu 
& Fazio, 2000). For colon cancer, total resection of the primary tumor with ample surgical 
margins and regional lymphadenectomy are the requisites for curative surgery. For rectal 
cancer, curative resection includes total excision of the mesorectum with adequate 
circumferential and distal surgical margins (R0) and lymphadenectomy along the inferior 
mesenteric vessels. Laparoscopic surgery has now become prevalent and safe, with long-
term oncological outcomes of CRC patients undergoing this surgery reported as comparable 
to those treated by the open surgical approach (Lacy et al., 2008; The Clinical Outcomes of 
Surgical Therapy Study Group, 2004). Within 5 years after curative surgical resection, 
disease relapse (tumor recurrence or metastasis) occurs in 40 to 50% of patients with stage III 
CRC and in 20% of those with stage II CRC (Midgley & Kerr, 1999). Systemic therapy with 
 
 Chemotherapeutic agents Therapeutic monoclonal antibodies 
 
5-FU 
Capecitabine Irinotecan Oxaliplatin Bevacizumab Cetuximab Panitumumab 
Target TS Topo-
isomerase I
DNA cross-
link 
VEGF EGFR EGFR 
Indication PO adjuvant
metastatic 
metastatic PO adjuvant
metastatic 
metastatic metastatic metastatic 
Combination       
  FOLFOX + LV  + combined combined combined 
  FOLFIRI + LV +  combined combined combined 
  FOLFOXIRI + LV + +    
Predictive 
markers 
TS, DPD, TP UGT1A1* ERCC-1 VEGF? 
Tumor 
micro-
vessels? 
EGFR 
copy 
number**, 
K-ras,  
B-raf, 
PI3CA, 
AREG, 
EREG 
K-ras, B-raf, 
PI3CA 
Table 1. Key agents and their combinations presently used for the treatment of CRC 
Abbreviations: AREG, amphyregulin; DPD, dihydropyrimidine dehydrogenase; EGFR, epidermal 
growth factor receptor; ERCC-1, excision-repair cross-complementing-1; EREG, epiregulin; 5-FU, 5-
fluorouracil; FOLFIRI, folinate, 5-FU and irinotecan; FOLFOX, folinate, 5-FU and oxaliplatin; 
FOLFOXIRI, FOLFOX and irinotecan; LV, leukovorin; PI3KCA, phosphoinositide 3 kinase (PI3K) p110 
catalytic subunit gene; PO, postoperative; TP, thymidine phosphorylase; TS, thymidylate synthase;  
UGT1A1, uridine diphosphate (UDP)-glucuronosyltransferase 1A1; VEGF, vascular endothelial growth 
factor.  
* The number of TA repeats in the TATA element in UGT1A1 gene predicts the drug toxicity and 
resultant adverse effects. 
** EGFR copy number is measured by fluorescence in-situ hybridization (FISH). 
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either chemotherapy and/or targeted therapies have been demonstrated to provide benefit 
to these CRC patients in both the post-operative adjuvant and advanced disease settings 
(Inoue et al., 2006; Midgley et al., 2009). Table 1 summarizes the key chemotherapeutic 
agents and therapeutic monoclonal antibodies targeting VEGF and EGFR and the 
combinations currently prescribed as adjuvant therapy for relapse-prone CRC patients and 
patients with metastatic tumors (reviewed in Cunningham et al., 2010; Meyerhardt & 
Mayer, 2005; Midgley et al., 2009; Wolpin et al., 2007; Wolpin & Mayer, 2008). The putative 
predictive markers for response to the respective agents are also shown in Table 1 (Walther 
et al., 2009). 
3.1 Adjuvant chemotherapy 
The purpose of postoperative adjuvant chemotherapy for stage II or III CRC is to destroy 
residual tumor cells and/or micrometastatic foci that are latent at the time of curative 
surgery. The chemotherapeutic mainstay for CRC, 5-fluorouracil (5-FU), exerts its anti-
tumor effect by inhibiting thymidylate synthase (TS), a critical enzyme for nucleic acid 
synthesis. Folinic acid (leucovorin: LV) is frequently used to enhance the anti-tumor effect of 
5-FU. The clinical and pharmacological rationale for this combination derives from the 
biological role of LV in stabilizing the ternary complex between TS and fluoro-deoxyuridine 
monophosphate (dUMP), an active metabolite of 5-FU, thereby enhancing TS inhibition. 
Adjuvant treatment regimens consist of oral (capecitabine) or infusional fluoropyrimidine-
based chemotherapy as a single agent with LV, or in combination with irinotecan (a 
topoisomerase I inhibitor), oxaliplatin (a DNA cross-linker) or both (Table 1) (Midgley et al., 
2009; Wolpin et al., 2007; Wolpin & Mayer, 2008).  
Adjuvant fluoropyrimidine-based chemotherapy reduces the risk of cancer-related mortality 
by 30% and increases the 5-year survival rate by 5-12% in patients with stage III (node-
positive) CRC. Adjuvant chemotherapy for stage II (node-negative) CRC patients is 
controversial because it increases the 5-year survival rate by just 3-4%. It has been proposed 
that “high-risk” stage II CRC patients characterized by T4 tumor, luminal stenosis or 
obstruction, poor histological differentiation, extramural vessel invasion, inadequate 
lymphadenectomy or surgical margins (R1) should preferentially undergo adjuvant 
chemotherapy (Cunningham et al., 2010; Midgley et al., 2009). Tumor relapse after curative 
resection occurs mostly within 3 years, irrespective of adjuvant chemotherapy (Sargent et 
al., 2007). Several clinical trials have failed to show a survival benefit from combining 
molecular target-directed agents (e.g., bevacizumab, cetuximab) with adjuvant 
chemotherapy (reviewed in Cunningham et al., 2010). Improvement in the survival of 
patients at high risk of tumor relapse therefore depends on intensive surveillance for early 
diagnosis of metastatic lesions, as well as identification of patients who are susceptible to 
tumor recurrence and who could thus benefit from more aggressive adjuvant treatment. 
3.2 Treatment of metastatic CRC 
A series of systemic, fluoropyrimidine-based combinatorial chemotherapies (Table 1) has 
substantially improved tumor response to treatment and increased the duration of 
progression-free and overall survival in patients with metastatic CRC. The remarkable 
advance in treating metastatic CRC in recent years has been due to the emergence and 
clinical application of molecular targeted therapeutics (Cunningham et al., 2010; Midgley et 
al., 2009). As stated above, a number of therapeutic monoclonal antibodies that target 
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relevant oncogenic pathways have been tested in clinical trials for CRC. Among them, the 
most widely used agents are bevacizumab, a recombinant humanized monoclonal antibody 
against VEGF (Ellis & Hicklin, 2008a; Li & Saif, 2009), cetuximab, a chimeric monoclonal 
antibody against EGFR (Balko et al, 2010) and panitumumab, a fully humanized monoclonal 
antibody against EGFR (Davis & Jimeno, 2010). These therapeutic antibodies have been used 
as monotherapy for the treatment of patients with metastatic CRC, or in combination with 
systemic chemotherapy (Table 1). Many clinical trials have demonstrated the additive effect 
of these antibodies on tumor response rate and progression-free survival (reviewed in 
Cunningham et al., 2010; Midgley et al., 2009). However, the combination of each 
therapeutic antibody with systemic chemotherapy regimens produced incremental but not 
always robust benefits to overall survival when compared to chemotherapy alone (Fojo & 
Parkinson, 2010). 
3.3 Obstacles to systemic therapy 
3.3.1 Drug resistance and predictive markers 
The major obstacles to systemic therapy for CRC include drug resistance (both inherent and 
acquired) and the lack of reliable biomarkers for predicting response or resistance to drugs 
in clinical use (Ellis & Hicklin, 2009). This has led to the recent trend of using intensive 
combinatorial regimens for advanced CRC patients. Surprisingly, some recent clinical trials 
have shown that combinatorial target-directed therapies resulted in decreased survival, 
inferior quality of life and unexpected detrimental effects (Douillard et al., 2010; Hecht et al., 
2009; Li & Saif, 2009; Tol et al., 2009).  
Understanding the molecular mechanisms that underlie drug resistance and identifying 
predictive markers for drug sensitivity are one and the same thing. Pharmacogenomic 
approaches (Furuta et al., 2009; Walther et al., 2009) have identified a number of factors 
involved in drug metabolism and secretion, some of which (e.g., UGT1A1 polymorphism) 
have been tested in clinical practice (Table 1). Several studies have suggested various 
biological mechanisms of resistance to VEGF-targeted cancer therapies (Bergers & Hanahan, 
2008; Ebos et al., 2008; Ellis & Hicklin, 2008b), but to date there are no clinically useful 
predictive markers. Mutational activation of oncogenic pathways that lie downstream of 
EGFR signaling is known to cause intrinsic resistance to therapies that target this receptor. 
This has led to the identification of predictive markers (e.g., K-ras, B-raf, PIK3CA) that allow 
better patient selection for such treatments (Banck & Grothey, 2009; Cantwell-Dorris et al., 
2011; De Roock et al., 2010a; Sartore-Bianchi et al., 2009). However, the complex pathways 
involved in tumor progression are often intercalated and therefore single markers cannot 
accurately predict the efficacy or outcome of CRC patients undergoing molecular targeted 
therapies (Baldus et al., 2010; De Roock et al., 2010b; Hecht et al., 2010). 
Research into the mechanisms of acquired resistance to molecular targeted agents has 
generated new therapeutic strategies and agents aimed at counteracting the resistance 
mechanism (Bowles & Jimeno, 2011; Cidón, 2010; Dasari & Messersmith, 2010; Presen et al., 
2010). Thus, improving the anti-tumor effects of molecular targeted therapies will depend 
on the identification of novel molecular pathways, development of new classes of rationally 
designed biological agents, and identification of predictive markers for response and 
resistance. 
3.3.2 Economic issues 
The high cost of developing the biologically-based therapeutic agents shown in Table 1 is a 
major issue in light of the modest clinical benefits, acquired drug resistance and lack of 
www.intechopen.com
 
Colorectal Cancer Biology – From Genes to Tumor 
 
112 
suitable predictive markers. A recent study reported significantly higher hospital costs for 
CRC patients with recurrence compared to those without (Macafee et al., 2009). Outside of 
the United States, the high cost of molecular targeted drugs has restricted their use to 
patients with sufficient income and/or health insurance. This issue highlights the 
importance of accurate predictive markers that allow identification of patients who are most 
likely to benefit from targeted agents, thus improving the cost effectiveness. 
4. GSK3 as an emerging therapeutic target 
4.1 GSK3 biology 
GSK3 was identified as a serine/threonine protein kinase that phosphorylates and inhibits 
glycogen synthase (GS), a rate-limiting enzyme in the regulation of glucose/glycogen 
metabolism in response to insulin-mediated signaling (Embi et al., 1980). In contrast to its 
original name and depending on its substrates and binding partners (Table 2) (Medina & 
Wandosell, 2011; Xu et al., 2009), GSK3 has been found to participate in many fundamental 
cellular pathways including proliferation, differentiation, motility, cell cycle and apoptosis 
(Doble & Woodgett, 2003; Harwood, 2001; Jope & Johnson, 2004; Nakada et al., 2011). The 
two isoforms of this kinase, GSK3ǂ and GSK3ǃ, are encoded by their respective genes. Their 
functions do not always overlap (Rayasam et al., 2009) and much recent attention has been 
directed towards the function of GSK3ǃ.  
Unlike most protein kinases, GSK3ǃ is active in normal cells and this activity is controlled 
by its subcellular localization, differential phosphorylation at serine 9 (S9) and tyrosine 216 
(Y216) residues, and different binding partners. A consensus motif and context-based 
computational analysis of in vivo protein phosphorylation sites indicate that GSK3ǃ is one of 
the kinases with the most substrates (Linding et al., 2007). In normal cells, multiple signaling 
pathways mediated by phosphoinositide 3 kinase (PI3K)-Akt, Wnt and mitogen-activated 
protein kinase (MAPK) are known to negatively regulate the activity of GSK3ǃ via S9 
phosphorylation (Medina & Wandosell, 2011). The molecular structure and details of the 
functional and regulatory machinery of GSK3ǃ have been thoroughly described in many 
excellent reviews cited in this section and are not the focus of this Chapter. 
4.2 GSK3 in common chronic diseases 
Accumulating evidence suggests pathological roles for GSK3ǃ in glucose intolerance due to 
inhibition of GS and other signaling cascades involved in the regulation of glucose homeo-
stasis (Frame & Zheleva, 2006; Lee & Kim, 2007) and in neurodegenerative changes through 
accumulation of the neurotoxic substances amyloid Aǃ and tau protein (Annaert & De 
Strooper, 2002; Bhat & Budd, 2002). Recognition that GSK3ǃ promotes inflammation also 
implicates this molecule in a broad spectrum of common diseases including type 2 diabetes 
mellitus and neuropsychiatric disorders involving an inflammatory reaction (Jope et al., 
2007). GSK3ǃ has therefore emerged as a therapeutic target in these prevalent diseases 
(Cohen & Goedert, 2004; Kypta, 2005; Meijer et al., 2004; Phukan et al., 2010). Another line of 
studies has demonstrated an osteogenic function for the Wnt/ǃ-catenin signaling pathway 
(Hartman, 2006; Krishnan et al., 2006; Ralston & de Crombrugghe, 2006). This suggests that 
GSK3ǃ may be a putative therapeutic target for osteoporotic bone disease, since under 
physiological conditions it is a well established member of a complex that destroys ǃ-catenin 
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Categories  Substrates 
Metabolism glycogen synthase, ATP citrate lyase, PKA, PDH, acetyl-CoA, 
carboxylase, PP1, PP2A, PP2A inhibitor, cyclin D1, eIF2B, NGF 
receptor, axin, APP, Bax, VDAC, hexokinase II, presenilin, LRP5/6 
Cell structure tau, MAP1B, NCAM, neurofilament, CRMP2, dynein, dynein-like 
protein, maltose binding protein, APC, kinesin light chain 
Signaling & Transcription  
   Wnt ǃ-catenin, snail, smad1, Hath1, smad 3 
   Akt SRC-3, B-cell lymphoma (BCL)-3, p21 
   PI3K-Akt Mcl-1, c-Jun, phosphatase and tensin homologue (PTEN) 
   Ras-PI3K-Akt c-Myc, cyclin D1 
   TNFǂ nuclear factor (NF)-κB 
   Hedgehog Ci (citrus interruptus), Gli-2 
   hypoxia hypoxia inducible factor (HIF)-1ǂ 
   insulin glycogen synthase, SREBP 
   undetermined &    
others 
cyclin E, AP-1, CREB, C/EBP, cdc25A, Notch, p53, p27Kip1, NFAT, 
GR, HSF-1, FGD-1, FGD-3, c-Myb, mCRY2, NACǂ, MafA, 
IPF1/PDX1, presenilin 1 C-terminal fragment 
Table 2. Known substrates for phosphorylation by GSK3ǃ 
Abbreviations: AP-1, activator protein 1; APC, adenomatous polyposis coli; APP, amyloid 
precursor protein; ATP, adenosine triphosphate; C/EBP, CCAAT (cytidine-cytidine-
adenosine-adenosine-thymidine)-enhancer-binding protein; CREB, cyclic adenosine 
monophosphate (cAMP) response element binding protein; CRMP2, collapsin response 
mediator protein 2; eIF2B, eukaryotic protein synthesis initiation factor-2B; FGD, FYVE, 
RhoGEF and PH domain-containing protein; GR, glucocorticoid receptor; HSF-1, heat shock 
factor protein 1; IPF1, insulin promoter factor 1; LRP5/6, low-density lipoprotein (LDL) 
receptor-related protein 5/6; MafA, musculoaponeurotic fibrosarcoma oncogene homolog 
A: MAP1B, microtubule-associated protein 1B; mCRY2, mouse cryptochrome 2; NACǂ, 
nascent polypeptide-associated complex ǂ subunit; NCAM, neural cell adhesion molecule; 
NFAT, nuclear factor of activated T-cells; NGF, nerve growth factor; PDH, pyruvate 
dehydrogenase; PDX1, pancreatic and duodenal homeobox 1; PKA, protein kinase A; PP, 
protein phosphatase; SREBP, sterol regulatory element-binding protein; TNFǂ, tumor 
necrosis factor ǂ; VDAC, voltage-dependent anion channel. 
(Fuchs et al., 2005). In this context, an orally bioavailable GSK3ǂ/ǃ dual inhibitor was 
generated and tested as a new drug for the treatment of osteoporosis (Kulkarni et al., 2006). 
4.3 GSK3 in cancer 
An increasing number of cellular structural and functional proteins have been identified as 
targets for GSK3ǃ phosphorylation-dependent regulation (Table 2). However, this has also 
generated results that show conflicting roles for the signaling pathways regulated by GSK3ǃ 
in either suppressing or promoting cancer. 
4.3.1 GSK3 suppresses cancer 
In physiologically normal cells, many of the substrates for GSK3ǃ-mediated phosphory-
lation and subsequent ubiquitin-mediated degradation include oncogenic signaling and 
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transcription factors, cell cycle regulators and proto-oncoproteins (Table 2). A previous 
study showed that GSK3ǃ phosphorylates and stabilizes a major cell cycle regulator, p27Kip1 
(Surjit & Lal, 2007). Recent studies have shown that inhibition of GSK3ǃ stabilizes snail and 
induces epithelial-mesenchymal transition (EMT), a morphological and phenotypic change 
closely associated with tumor cell invasion and metastasis (Bachelder et al., 2005; Zhou et 
al., 2004; reviewed in Doble & Woodgett, 2007; Schlessinger & Hall, 2004; Zhou & Hung, 
2005). These findings are mostly observed in normal but not neoplastic cells and have led to 
the hypothesis that GSK3ǃ functions as a tumor suppressor (reviewed in Luo, 2009; 
Manoukian & Woodgett, 2003; Patel & Woodgett, 2008). 
Consistent with this hypothesis, a number of studies in breast, lung and non-melanoma skin 
cancers have shown that GSK3ǃ is inactivated in tumor cells, but that its activation induces 
apoptosis (reviewed in Luo, 2009; Patel & Woodgett, 2008). It has been reported in several 
studies that GSK3ǃ renders cancer cells resistant to chemotherapeutic agents (reviewed in 
Luo, 2009). However, in contrast to the observations described in the next section (4.3.2), 
including our own, none of these studies addressed differences in the expression, activity 
and biological properties of GSK3ǃ between tumor cells and their normal cell counterparts. 
Furthermore, these studies did not investigate the direct consequences of GSK3ǃ inhibition 
for tumor cell survival, proliferation and chemotactic migration and invasion. 
4.3.2 Deregulated GSK3 promotes cancer 
Wnt signaling plays a crucial role in embryonic development, the regeneration of adult 
tissues and in many other cellular processes. Aberrant activation of the Wnt pathway due to 
mutation or deregulated expression of its components mediates the multistep process of 
colorectal tumorigenesis (Kikuchi, 2007; Klaus & Birchmeier, 2008; Lustig & Behrens, 2003; 
Willert & Jones, 2006). Over 90% of CRC develops following activation of the Wnt signaling 
pathway in which ǃ-catenin plays a central role (Fuchs et al., 2005; Giles et al., 2003). GSK3ǃ 
interrupts activation of the canonical Wnt pathway by phosphorylating ǃ-catenin and 
recruiting it to ubiquitin-mediated degradation. GSK3ǃ is therefore believed to antagonize 
tumorigenesis that involves active Wnt signaling (Bienz & Clevers, 2000; Manoukian & 
Woodgett, 2002; Polakis P, 1999), as represented for example by CRC development. This 
notion is also supported by the frequent mutational activation of Ras and PI3K-Akt 
signaling (Markowitz & Bertagnolli, 2009; Parsons et al., 2005), since it is well established 
that Akt kinase phosphorylates the S9 residue of GSK3ǃ and inhibits its activity (Medina & 
Wandosell, 2011). However, few studies had focused on the biological properties of GSK3ǃ 
in cancer until we investigated a putative pathological role for this kinase in CRC, as 
described below. 
Most CRC cell lines and primary CRC tumors in our studies have shown increased 
expression and activity of GSK3ǃ and deregulation of its activity due to imbalance in the 
differential phosphorylation of S9 (inactive) and Y216 (active) residues. This is in 
comparison to non-neoplastic cells (e.g., HEK293) and normal colon mucosa in which 
GSK3ǃ activity appears to be regulated by the differential phosphorylation. These tumor cell 
features are unrelated to the activation of ǃ-catenin or Akt (Mai et al., 2009; Shakoori et al., 
2005). A non-radioisotopic, in vitro kinase assay demonstrated an increased ability of GSK3ǃ 
derived from most CRC cell lines and primary CRC tumors to phosphorylate its substrate, 
as compared to non-neoplastic counterparts (Mai et al., 2006, 2009). These observations 
suggest that, in contrast to having hypothetical tumor suppressor function, GSK3ǃ may 
actually promote cancer.  
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A putative pathological role for GSK3ǃ in cancer was demonstrated by subsequent 
observations that inhibition of GSK3ǃ activity using pharmacological (small-molecule) 
agents and of its expression by RNA interference reduced the survival and proliferation of 
CRC cells. Such inhibition also predisposed the cells to apoptosis in vitro and in tumor 
xenografts, suggesting that CRC cells depend on aberrant GSK3ǃ for their survival and 
proliferation (Mai et al., 2006, 2009; Shakoori et al., 2005, 2007). A series of studies by our 
group led us to propose that aberrant GSK3ǃ is a novel and potentially important 
therapeutic target in cancer (Miyashita et al., 2009b; Motoo et al., 2011; Nakada et al., 2011), 
thus allowing us to apply for domestic and international patents in this field (Minamoto).  
Following our studies on the antitumor effects of GSK3ǃ inhibition, similar observations 
were reported for CRC by other groups (Ghosh & Altieri, 2005; Rottmann et al., 2005; Tan et 
al., 2005; Tsuchiya et al., 2007) (Table 3). Similar results were also published for other cancer 
types with underlying biological mechanisms that included GSK3ǃ inhibition of several 
pathways involved in tumorigenesis (reviewed in Miyashita et al., 2009b; Nakada et al., 
2011). A putative role for GSK3ǃ in cancer is still being debated (Luo, 2009; Manoukian & 
Woodgett, 2003; Patel & Woodgett, 2008) and was discussed in section 4.3.1. However, the 
overall results to date indicate that aberrant expression and activity of GSK3ǃ is likely to be 
a common and fundamental characteristic of a broad spectrum of human cancers. 
4.3.3 Oncogene addiction and the effect of GSK3 inhibition against cancer 
As stated in section 2.2, the hypothesis of oncogene addiction has been proposed as a 
rationale for molecular targeting in cancer treatment. It refers to the observation that a 
cancer cell, despite its plethora of genetic alterations, seemingly exhibits dependence on a 
single oncoprotein or oncogenic pathway for its sustained survival and/or proliferation 
(Sharma & Settleman, 2007; Weinstein, 2002; Weinstein & Joe, 2006). This unique state of 
dependence by cancer cells is highlighted by the fact that inactivation of the normal 
counterpart of such proto-oncogene products in non-neoplastic cells is tolerated without 
obvious consequence. A profound implication of this hypothesis is that acute interruption of 
the critical oncogenic pathways upon which cancer cells are dependent should have a major 
detrimental effect (oncogene shock), while sparing normal cells that are not similarly 
addicted to these pathways (Sharma et al, 2006). In our series of studies, inhibition of GSK3 
had little effect on cell survival, growth, apoptosis or senescence in non-neoplastic cells (e.g., 
HEK293) and on major vital organs in rodents (Mai et al., 2006, 2009; Shakoori et al., 2005, 
2007). This concurs with previous reports showing that GSK3 inhibition does not influence 
the survival or growth of human mammary epithelial cells, embryonic lung fibroblasts 
(WI38) and mouse embryonic fibroblasts (NIH-3T3) (Kunnimalaiyaan et al., 2007; Ougolkov 
et al., 2005). With respect to the oncogene addiction hypothesis (Sharma & Settleman, 2007; 
Weinstein, 2002; Weinstein & Joe, 2006), the selective therapeutic effect of GSK3 inhibition 
against cancer can be explained by differences in biological properties of GSK3ǃ between 
neoplastic and non-neoplastic cells (Mai et al., 2006, 2009; Shakoori et al., 2005). 
5. GSK3 and the hallmarks of colorectal cancer 
Understanding the molecular mechanism behind a pathogenic role for GSK3 in cancer is 
important for the development of treatment strategies that target this kinase. A current 
review highlights 8 hallmarks of cancer in which phenotypic properties are progressively  
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Authors 
Study 
design 
Types of 
GSK3ǃ 
inhibitors 
Pathological roles of GSK3ǃ and underlying 
mechanism 
Shakoori et 
al, 2005 
in vitro AR-A014418, 
SB-216763, 
siRNA 
Deregulated GSK3ǃ expression and activity are 
associated with CRC cell survival and 
proliferation by mechanism independent of 
activation of Wnt/ǃ-catenin signaling and Akt. 
GSK3ǃ inhibition attenuates survival and 
proliferation of colon cancer cells. 
Mai et al, 
2006 
in vitro AR-A014418, 
SB-216763, 
siRNA 
NRIKA detected higher activity of GSK3ǃ for 
phosphorylating its substrate (ǃ-catenin) in 
gastrointestinal cancer cells including CRC cells 
than non-neoplastic HEK293 cells. 
Shakoori et 
al, 2007 
tumor 
xenograft 
AR-A014418, 
SB-216763 
GSK3ǃ inhibition attenuates survival and 
proliferation of SW480 colon cancer cell 
xenografts with no detrimental effects on the 
major vital organs in the rodents. 
Mai et al, 
2009 
in vitro, 
tumor 
xenograft 
AR-A014418, 
SB-216763, 
siRNA 
GSK3ǃ inhibition attenuates survival and 
proliferation of colon cancer cells by decreasing 
hTERT expression and telomerase activity and 
inducing cell senescence. 
Ghosh et 
al, 2005 
in vitro LiCl, TDZD8, 
SB-216763, 
siRNA 
GSK3ǃ functions against activation of p53-
dependent apoptosis in colon cancer cells. 
Tan et al, 
2005 
in vitro LiCl, SB-
216763, 
SB415286, 
LY2119301 
GSK3ǃ functions against activation of p53-
dependent apoptosis through a direct Bax-
mediated mitochondrial pathway in colon 
cancer cells. 
Rottmann 
et al, 2005 
in vitro, 
tumor 
xenograft 
LiCl, siRNA GSK3ǃ functions against colon cancer cell 
apoptosis by inhibiting a TRAIL receptor-
dependent synthetic lethal relationship between 
Myc activation and FBW7 loss of function. 
Tsuchiya 
et al, 2007 
in vitro BIO, LiCl, 
keupaullone 
GSK3ǃ inhibits colonocyte differentiation by 
destabilizing the transcription factor, Hath1. 
Table 3. Pathological roles and functions of GSK3ǃ in colorectal cancer 
Abbreviations: hTERT, human telomerase reverse transcriptase; NRIKA, non-radioisotopic 
in vitro kinase assay; siRNA, small interfering RNA; TRAIL, tumor necrosis factor (TNF)-
related apoptosis-inducing ligand. 
acquired during multistep pathogenesis, thus allowing cancer cells to become tumorigenic 
and ultimately malignant (Hanahan & Weinberg, 2011). These hallmarks are sustained 
proliferative signaling, evasion of growth suppressors, resistance to cell death, enabling of 
replicative immortality, induction of angiogenesis, activation of invasion and metastasis, 
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reprogramming of energy metabolism and evasion of immune destruction. The 
development of each hallmark involves multiple signaling pathways. In this section, we 
address how GSK3 modulates some of these hallmark characteristics of CRC by referring 
to the studies shown in Table 3, including our own work. 
5.1 Cell proliferation 
Unrestrained cell proliferation is the most prominent feature of cancer. Our previous study 
showed that the effect of GSK3 inhibition against the proliferative capacity of CRC cells 
was associated with decreased expression of cyclin D1 and cyclin-dependent kinase (CDK) 6 
and phosphorylation of the Rb protein (Mai et al., 2009). These observations suggest that Rb 
function was restored, leading to the binding and inhibition of E2F transcription factor 
(reviewed in Classon & Harlow, 2002; Knudsen & Knudsen, 2008). This is consistent with a 
subsequent report that forced expression of exogenous GSK3 promotes the proliferation of 
ovarian cancer cells by inducing cyclin D1 expression (Cao et al., 2006). Together, the results 
suggest that suppression of excess cancer cell proliferation via the inhibition of GSK3 is 
partly due to negative regulation of cell cycling by cyclin D1. In normal or non-neoplastic 
cells, cyclin D1 is one of the primary targets of GSK3ǃ for phosphorylation and subsequent 
degradation in the ubiquitin-proteasome system (Diehl et al., 1998) (Table 2). The opposing 
role of GSK3ǃ in cyclin D1 expression may explain the lack of effect of GSK3ǃ inhibition on 
cell survival and growth of non-neoplastic cells found in earlier studies (Kunnimalaiyaan et 
al., 2007; Mai et al., 2009; Ougolkov et al., 2005; Shakoori et al., 2005). 
5.2 Resistance to cell death via tumor suppressor pathways 
A major mechanism by which cancer cells evade cell death is via the inactivation of tumor 
suppressor pathways mediated by p53 (Royds & Iacopetta B, 2006; Vousden & Lane, 2007; 
Zilfou & Lowe, 2009) and Rb (Classon & Harlow, 2002; Knudsen & Knudsen, 2008). The 
studies listed in Table 3 showed that inhibition of GSK3ǃ induced apoptosis in human CRC 
cell lines. This effect was associated with increased expression of p53 and of p21 in colon 
cancer cells with wild-type p53, and decreased Rb phosphorylation in colon cancer cells 
irrespective of their p53 status (Ghosh & Altieri, 2005; Mai et al., 2009; Tan et al., 2005). 
Another study showed that GSK3ǃ suppresses the apoptosis of colon cancer cells by 
inhibiting a tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) 
receptor-dependent synthetic lethal relationship between c-Myc activation and FBW7 (a 
gene encoding a ubiquitin ligase receptor) loss of function (Rottmann et al., 2005). These 
studies suggest a putative pathological role for aberrant GSK3ǃ in mediating CRC cell 
resistance to apoptosis induced by a pathway involving tumor suppressor proteins, TRAIL 
and c-Myc.  
One of the representative pathways for cell survival is mediated by nuclear factor-κB (NF-
κB) (Inoue et al., 2007; Karin, 2006, 2009). Based on previous studies showing the potential 
involvement of GSK3ǃ in NF-κB-mediated cell survival during mouse embryonic 
development (Hoeflich et al., 2000; Schwabe & Brenner, 2002), it was reported that GSK3ǃ 
sustains pancreatic cancer cell survival by maintaining transcriptional activity of NF-κB 
(Ougolkov et al., 2005; Wilson & Baldwin, 2008). While these studies examined the activity 
of exogenous (transfected) NF-κB, we previously observed no effect of GSK3ǃ inhibition on 
endogenous NF-κB transcriptional activity in gastrointestinal cancer cells (including CRC) 
and glioblastoma cells (Mai et al., 2009; Miyashita et al., 2009a). Therefore, a role for GSK3ǃ 
in regulating NF-κB activity in cancer is controversial. 
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5.3 Replicative cell immortality 
Another critical mechanism used by cancer cells to evade cell death is replicative cell 
immortality. A close relationship exists in cancer cells between the molecular mechanisms 
for immortality and escape from replicative senescence (Finkel et al., 2007). Cancer cells 
acquire constitutive expression and activity of human telomerase reverse transcriptase 
(hTERT) and telomerase in order to circumvent telomere-dependent pathways of cell 
mortality (Harley, 2008).  
We recently observed a decreased level of hTERT mRNA in colon cancer cells following 
inhibition of either the activity or expression of GSK3ǃ. Inhibition of GSK3ǃ attenuates 
telomerase activity and increases the ǃ-galactosidase-positive (senescent) population in 
colon cancer cells. These effects were associated with increased expression of p53, p21 and c-
Jun N-terminal kinase 1 (JNK1) and decreases in CDK6 expression and Rb phosphorylation 
(Mai et al., 2009). The findings are consistent with the known relationship between these 
proteins and cell senescence (reviewed in Kiyono, 2007) and with GSK3ǃ activity (Ghosh & 
Altieri, 2005; Kulikov et al., 2005; Liu et al., 2004; Mai et al., 2009; Qu et al., 2004; Rössig et al., 
2002). Consistent with our observation, a recent study found that inhibition of GSK3ǃ 
suppressed hTERT expression and telomerase activity and shortened the telomere length in 
various cancer cell lines including HCT116 colon cancer cells, and attenuated cell 
proliferation and hTERT expression in ovarian cancer xenografts (Bilsland et al., 2009). The 
putative role for GSK3ǃ in protecting cancer cells from telomere-dependent senescence and 
mortality is attributed to its effects on hTERT expression and telomerase activity. 
5.4 Influence on the cancer microenvironment and tumor invasion 
In cancer, various events are orchestrated to produce a distinct tumor microenvironment 
that dictates the malignant potential. These include depletion of nutrients involved in cell 
proliferation, tumor cell invasion, tumor neovascularization in response to hypoxic 
condition, as well as stromal, inflammatory and immune reactions in the host (Joyce, 2005). 
The promotion of inflammation and immune response by GSK3ǃ (Jope et al, 2007) suggests 
a broad pathological role for this kinase in the cancer microenvironment.  
The pro-invasive phenotype of cancer cells is characterized by EMT, enhanced cell motility 
and their ability to induce neovascularization. As discussed in section 4.3.1, inhibition of 
GSK3ǃ stabilizes snail and induces EMT (Bachelder et al., 2005; Zhou et al., 2004; reviewed 
in Doble & Woodgett, 2007; Schlessinger & Hall, 2004; Zhou & Hung, 2005). A hypoxic 
tumor microenvironment induces the expression of hypoxia-inducible factor-1ǂ (HIF-1ǂ), a 
transcription factor that controls oxygen homeostasis by regulating target genes involved in 
angiogenesis, glycolysis and cell proliferation (reviewed in Semenza, 2009). A previous 
study showed that under physiological conditions, GSK3ǃ inhibits angiogenesis by 
negatively regulating endothelial cell survival and migration in response to PI3K-, MAPK- 
and protein kinase A (PKA)-dependent signaling pathways (Kim et al., 2002). Another study 
demonstrated that hypoxia induces a biphasic effect on HIF-1ǂ stabilization in liver cancer 
cells. Accumulation of HIF-1ǂ occurs in early hypoxia and is dependent on an active 
PI3K/Akt pathway and inactive GSK3ǃ. In contrast, prolonged hypoxia results in the 
inactivation of Akt and activation of GSK3ǃ. This negatively regulates HIF-1ǂ activity by 
inhibiting its accumulation (Mottet et al., 2003). Collectively, it thus appears unlikely that 
GSK3ǃ participates in cancer cell EMT and in tumor angiogenesis. 
Formation of lamellipodia, the characteristic cellular microarchitecture, is responsible not 
only for cell migration under physiological conditions (e.g., embryonic development, 
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wound healing) but also for cancer cell migration and invasion (Machesky, 2008; Small et al., 
2002; Yilmaz & Christofori, 2009). A member of the Rho-GTPase family, Rac1, is known to 
participate in the formation of lamellipodia and may thus play an important role in cancer 
progression (Raftpoulou & Hall, 2004; Sahai & Marshall, 2002). It has been reported that 
GSK3ǃ participates in cell motility by facilitating the formation of lamellipodia (Koivisto et 
al., 2003) and by activating Rac1 (Farooqui et al., 2006; Kobayashi et al., 2006; Vaidya et al., 
2006). Focal adhesion kinase (FAK) is also known to play a key role in regulating cell 
motility and migration and to be deregulated in cancer (McLean et al., 2005). Earlier studies 
reported that FAK is one of the downstream effectors in GSK3ǃ-mediated pathways 
(Kobayashi et al., 2006) and also regulates Rac1 (McLean et al., 2005). Consistent with a recent 
study for glioblastoma (Nowicki et al., 2008), our preliminary study has shown that inhibition 
of GSK3ǃ attenuates pancreatic cancer cell migration and invasion by negatively regulating 
FAK and Rac1 activities (unpublished observation). Therefore, in regard to cancer treatments 
that target GSK3ǃ, it is important to explore a possible role for GSK3ǃ in CRC cell invasion by 
investigating its effects on cellular microarchitecture, motility and migration. 
5.5 Cancer cell stemness and metabolic traits 
Cell stemness and the reprogramming of energy metabolism are primary cell characteristics 
that share distinct molecular pathways and allow cancer cells to survive, proliferate, invade 
their host tissues, metastasize and resist treatment. Here, we address future directions in our 
approach towards ascertaining the potential of GSK3ǃ as a therapeutic target in cancers 
including CRC. 
5.5.1 Cancer cell stemness and GSK3 
Arising from the concept of tissue stem cells, the notion of cancer stem cells has emerged 
and proposes that cancer initiating cells are a distinct subpopulation within a tumor that 
have the ability to self-renew and differentiate (Clarke et al., 2006; O’Brien et al., 2010). 
Similar to other cancer types, a small population of cancer initiating cells has been identified 
and characterized in CRC (Dalerba et al., 2007; O’Brien et al., 2007; Ricci-Vitiani et al., 2007; 
reviewed in Yeung & Mortensen, 2009). Current cancer treatments assume that all cancer 
cells in tumors are homogeneous and have a similar capacity to proliferate, invade and 
metastasize, as well as having similar susceptibility to chemotherapy and radiation. 
However, accumulating evidence suggests that cancer stem cells and cancer cells that are 
undergoing EMT share various biological traits (Polyak & Weinberg, 2009). These cells are 
also strongly resistant to current forms of therapeutics, thereby identifying this 
subpopulation of cancer cells as the ultimate target for cancer treatment (Lou & Dean, 2007). 
Consistent with the physiological roles of GSK3 in Wnt, Hedgehog and Notch signaling 
(Foltz et al., 2002; Manoukian & Woodgett, 2002; Takenaka et al., 2007), GSK3ǃ inhibition by 
pharmacological means promotes embryonic stem cell pluripotency (Sato et al., 2004) and 
hematopoietic stem cell reconstitution (Trowbridge et al., 2006). Conversely, recent studies 
have demonstrated that GSK3ǃ sustains the respective molecular pathways leading to 
tumor cell stemness in a specific type of leukemia and in glioblastoma (Korur et al., 2009; 
Wang et al., 2008). Although the underlying molecular mechanisms are not well understood, 
these differential roles for GSK3 in normal and cancer stem cells could ultimately benefit 
cancer treatment strategies by allowing this kinase to be targeted with little harm to patients. 
As addressed in the next section (5.5.2), anaerobic glycolysis and the presence of a distinct 
niche are thought to be characteristics of cancer stem cells, in addition to their extreme 
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resistance to drug treatment. Therefore, clarification of a putative role for GSK3 in 
regulating CRC cell stemness is of great interest. This could lead to a new strategy for 
treatment that targets the biology of cancer cell stemness. 
5.5.2 Distinct metabolic traits of cancer cells and GSK3 
Production of excess energy is thought to provide an intrinsic and selective pressure that 
allows cancer cells to expand clonally and to acquire immortalized and destructive 
phenotypes. Even under normoxic conditions, most cancer cells depend on increased 
glucose uptake and aerobic glycolysis to produce their energy source, adenosine 
triphosphates (ATP) (Kim & Dang, 2006; Vander Heiden & Cantley, 2010). This is known as 
the Warburg effect and involves truncated oxidative phosphorylation in the tricarboxylic 
acid (TCA) cycle, thus resulting in mitochondrial uncoupling (Samudio et al., 2009). These 
properties allow cancer cells to survive and invade host tissues in a microenvironment 
where the supply of both oxygen and nutrients is deficient, as well as conferring resistance 
to apoptosis-inducing therapeutic stimuli (Smallbone et al., 2007). Therefore, the glycolytic 
phenotype of cancer cells is a potential target for cancer diagnosis and treatment (Gatenby & 
Gillies, 2007; Kroemer & Pouyssegur, 2008). For example, enhanced glucose uptake by 
cancer cells can be used to visualize cancer by positron emission tomography (PET) using 
the radioisotope-labeled glucose analogue 2-[18F]-fluoro-2-deoxy-D-glucose (FDG). FDG-
PET in combination with computed tomography (PET-CT) enables the detection of 
metastatic lesions for most cancers with sensitivity and specificity both greater than 90% 
(Mankoff et al., 2007).  
The association between a glycolytic phenotype (i.e., TCA cycle defects) and resistance to 
apoptosis is attributed to decreased mitochondrial hydrogen peroxide production and 
cytochrome C release (Samudio et al., 2009; Vander Heiden & Cantley, 2010). Pyruvate 
dehydrogenase (PDH) plays a crucial role in triggering the TCA cycle by converting 
pyruvate to citric acid. PDH kinase 1 (PDK1), which phosphorylates and inactivates PDH, is 
frequently over-activated in cancer cells, resulting in an impaired TCA cycle and 
mitochondrial hyperpolarization. Thus, inhibition of PDK1 would re-activate PDH and 
restore mitochondrial membrane polarity, thereby facilitating cancer cell apoptosis in 
response to chemotherapeutic agents and radiation. Dichloroacetate (DCA), an orally bio-
available small molecule, is a well characterized PDK1 inhibitor. The ability of DCA to 
inhibit lactate production by stimulating PDH and the TCA cycle has long been used to treat 
lactic acidosis, which is a complication of inherited mitochondrial disorders (Stacpoole, 
2003, 2006). A recent study demonstrated that DCA induces cancer cell apoptosis by 
selectively inhibiting PDK1 in cancer cells, leading to metabolic remodeling from glycolysis 
to glucose oxidation and the normalization of mitochondrial function (Bonnet et al., 2008). A 
clinical trial of oral DCA in children with congenital lactic acidosis reported that DCA was 
well tolerated and safe (Stacpoole, 2006). Thus, orally administered DCA is a promising and 
selective anticancer agent.  
The primary role of GSK3ǃ is to control GS activity (Table 2). It thus acts as a checkpoint at 
the bifurcation between glycogenesis and glycolysis, the two major pathways of 
glucose/glycogen metabolism (Lee & Kim, 2007). We recently found that inhibition of 
GSK3ǃ in colon cancer cells increased GS expression and decreased its S640 phosphorylation 
(unpublished observation), suggesting that GSK3ǃ inhibition may switch cancer cells from a 
glycolytic to a glycogenic phenotype. It was previously reported that GSK3ǃ phosphorylates 
and inactivates PDH (Hoshi et al., 1996) (Table 2), a key enzyme for the TCA cycle in 
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mitochondria. This suggests that deregulated GSK3ǃ contributes to truncation of the TCA 
cycle and mitochondrial uncoupling in cancer cells, resulting in resistance to chemotherapy 
and radiation. It has also been reported that the distinct metabolism of cancer cells involves 
not only anaerobic glycolysis but also other metabolic pathways such as the pentose 
phosphate pathway, amino acid and nucleic acid synthesis and glutaminolysis 
(DeBerardinis et al., 2008). GSK3ǃ has a number of key metabolic enzymes as substrates 
(Table 2), suggesting this molecule could have broad control over various pathological 
metabolic pathways in cancer cells. 
6. Perspectives 
Biologically-based therapy of cancer holds great promise, particularly for patients who are 
refractory to existing forms of therapy. Current paradigms reviewed in the earlier part of 
this Chapter (3. Systemic treatment: an overview) include the targeting of growth factor 
receptor-type protein tyrosine kinases and angiogenic factors. Such therapies are directed 
against cancer cell survival, proliferation and tumor angiogenesis; however they are unable 
to completely eradicate cancer, as demonstrated by most large-scale clinical trials.  
 
 
Fig. 1. GSK3ǃ promotes cell stemness, invasive capacity and excess glucose metabolism that 
interact to produce a distinct cancer microenvironment. 
The distinct pathologic properties of GSK3ǃ in cancer described here highlight its potential to 
be an innovative target for the radical treatment of this disease, including CRC. GSK3ǃ can 
potentially promote cancer cell stemness, invasive capacity and glucose metabolism, thus 
creating the selective pressures that allow cancer cells to persist in a distinct microenvironment 
(Figure 1). Understanding the complex biological mechanisms for the multiple roles of GSK3ǃ 
in promoting cancer should allow elucidation of novel molecular pathways that lead to cancer 
development and progression. This will also provide a detailed scientific basis for the 
development of cancer treatment strategies that target aberrant GSK3ǃ. 
Concerns regarding the therapeutic use of GSK3ǃ inhibitors remain because these may 
activate oncogenic (e.g., Wnt) signaling, thus promoting cell proliferation (Manoukian & 
Woodgett, 2003). However, this issue has not deterred preclinical studies of GSK3ǃ 
inhibitors for the treatment of many cancer types (reviewed in Miyashita et al., 2009b) or 
Phase II clinical trials for the treatment of neurological diseases (Chico et al., 2010). 
Currently, two clinical trials are being undertaken to test a pharmacological GSK3ǃ inhibitor 
(LY2090314) for enhancement of the anti-tumor effect of chemotherapeutic agents for 
advanced solid cancer (phase I: http://clinicaltrials.gov/ct2/show/study/NCT01287520) 
and leukemia (phase II: http://clinicaltrials.gov/ct2/show/study/NCT01214603). Such 
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trials targeting GSK3ǃ should complement, enhance or substitute the current front line 
therapies that target growth factor receptors and angiogenic factors in refractory colorectal 
cancer. 
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